The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Open accessAbstract
T cells promote immunosuppression in melanoma through CSF1 induction and macrophage recruitment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“numerous studies of patients with cancer have indeed found that these myeloid cell subsets, whether in the tumor or in peripheral tissues, were negatively correlated with effective ICI therapy (134, 161, 168-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Forget, M. A., Voorhees, J. L., Cole, S. L., Dakhlallah, D. A., Patterson, I. L., Gross, A. C., Moldovan, L., Mo, X. M., Evans, R., Marsh, C. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098623 · Cited by 94
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“The induction of PDL1 on cancer cells and tumor-associated stromal cells was shown to be directly mediated by IFN signaling (51), one of the main cytokines secreted by activated CD8+ T and CD4+ helper 1 T cells.”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“2 of 14 markers, such as expression of PDL1 in the tumors, high intratumoral T cell infiltration, or the abundance of tumor-specific T cells (40, 41).”
BackgroundCharoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Research works printed but not linked: 2
- T. M. Therneau P. M. Grambsch Modeling Survival Data: Extending the Cox Model (Springer Science & Business Media 2013).
- 10.1002/(SICI)1097-0215(19970917)72:6<1045::AID-IJC20>3.0.CO;2-2 · doi:10.1002/(sici)1097-0215(19970917)72:6<1045::aid-ijc20>3.0.co;2-2
Cited by
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Tumor-Associated Macrophages in Tumor Immunity
Pan, Y., Yu, Y., Wang, X., & Zhang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583084 · Cited by 1,872
“Also, combination of anti-PD-1 and anti-CSF1R antibodies induces melanoma regression in mice (66).”
Background
Metadata
- Authors
- Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., Klaman, I., Danenberg, E., Ioannidou, K., Kandalaft, L., Coukos, G., Hoves, S., Ries, C. H., Fuertes Marraco, S. A., Foukas, P. G., De Palma, M., & Speiser, D. E.
- Affiliations
- Ludwig Cancer Research (CH)
- École Polytechnique Fédérale de Lausanne (CH)
- Ludwig Cancer Research Center and Department of Oncology, University of Lausanne (UNIL), CH-1066 Epalinges, Switzerland.
- Yale University (US)
- Roche Pharma AG (Germany) (DE)
- Centre Hospitalier Universitaire Vaudois (CH)
- Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
- Corresponding author
- Neubert, Natalie J.
- Schmittnaegel, Martina
- Bordry, Natacha
- Speiser, Daniel E.
- ORCID
- Neubert, Natalie J.
- Schmittnaegel, Martina
- Bordry, Natacha
- Nassiri, Sina
- Wald, Noémie
- Martignier, Christophe
- Tillé, Laure
- Damsky, William
- Maby-El Hajjami, Hélène
- Klaman, Irina
- Danenberg, Esther
- Ioannidou, Kalliopi
- Kandalaft, Lana
- Coukos, George
- Hoves, Sabine
- Ries, Carola H.
- Foukas, Periklis G.
- De Palma, Michele
- Speiser, Daniel E.
- Venue
- Science Translational Medicine
- Published
- 2018-04-11
- Volume
- 10
- Issue
- 436
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5957531
- OpenAlex
- W2797752921
- Cited by
- 308
- References
- 108
- Citations by year
- 2026: 13 · 2025: 28 · 2024: 26 · 2023: 44 · 2022: 48 · 2021: 54 · 2020: 49 · 2019: 36 · 2018: 9
- FWCI
- 13.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Cancer Research Institute (0)
- Swiss National Science Foundation (CRSII3-160708, 31003A-165963)
- Fondation Leenaards (0)
- Emma Muschamp Foundation (0)
- Swiss Cancer Research (3507-08- 2014)
- Swiss TransMed (KIP 18)
- Alfred and Annemarie von Sick (0)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- melanoma, CSF-1, CSF1R, anti-PD-1 therapy, immune checkpoint inhibitor resistance, T cells, adaptive resistance, immunotherapy resistance, CSF1R inhibition
- MeSH terms
- CD163 Antigen, Animals, Cell Differentiation, Humans, Macrophages, Melanoma, Receptors, Cell Surface, Antigens, Differentiation, Myelomonocytic, Signal Transduction, Antigens, CD, Macrophage Colony-Stimulating Factor, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T cell–induced CSF1 promotes melanoma resistance to PD1 blockade. https://app.cochat.ai/papers/10.1126/scitranslmed.aan3311
- The paper
- Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., Klaman, I., Danenberg, E., Ioannidou, K., Kandalaft, L., Coukos, G., Hoves, S., Ries, C. H., Fuertes Marraco, S. A., Foukas, P. G., . . . Speiser, D. E. (2018). T cell–induced CSF1 promotes melanoma resistance to PD1 blockade. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aan3311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.